Usage of Mexidol in patients with dystrophic diseases of posterior eye segment

Author:
E.A. EGOROV, B.V. OBRUCH, A.I. OLEINIK, L.S. BORDASHEVSKAYA, M.R. KURBANOVA
Department of Ophthalmology, GOU VPO Russian State Medical University of Roszdrav Municipal Clinical Hospital 15, named after Filatov

Summary:
Purpose: to evaluate the efficacy of Mexidol in patients with glaucomatous optic neuropathy. Materials and methods: 139 patients with glaucomatous optic neuropathy were divided into 3 groups: 45 patients received Mexidol, 46 – combined treatment by Mexidol, Treantal, Kavinton and Solcoseryl, 48 – were included in the control group. Examination was carried out before treatment and in 10 days after the beginning: evaluation of visual acuity, retinal light sensitivity, perimetry, retinotomography. Results: Visual acuity increased by 0.05–0.2 in 41 patients of the first group. Average peripheral visual field enlarging by 60–110 degrees was found in 35 patients. In 38 patients light sensitivity of the retina improved
by 3–5.9. In the second group improvement of visual acuity was detected in 39 subjects by 0.05–0.3, peripheral field enlargement– by 80–140 degrees in 41 patients and light sensitivity by 4.71 – in 42 patients.

Conclusion: Combined treatment including Mexidol allows achieving better results in treatment of patients with glaucomatous optic neuropathy.